Work

Number needed to treat to avoid progression or death: Zanubrutinib vs other COVALENT bruton tyrosine kinase inhibitors in Relapsed/Refractory chronic lymphocytic leukemia

Year: 2025

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2025-4553

Authors: Mazyar Shadman, Jennifer Brown, David Campbell, Mei Xue, Marjan Massoudi, Rhys Williams, Keri Yang, Constantine Tam

Institutions: Mayo Clinic in Florida, Dana-Farber Cancer Institute, The Alfred Hospital, Monash University

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4417018416

Cites:

Cited by:

Related to: